atezolizumab and bevacisumab for mesotheioma -pro
Malignant peritoneal mesothelioma is a rare but aggressive disease with historically poor survival and limited treatment options. A phase II study published by Kanwal Raghav, MBBS, MD, and colleagues in Cancer Discovery found that combination treatment with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab was well tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, rare cancer in the lining of the abdomen. Responses occurred in patients regardless of PD-L1 expression status and tumor mutational burden. Trial results also indicated that the combination was safe and effective in patients with disease progression or intolerance to previous chemotherapy treatment.
K. Raghav et al, Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov (2021) 11 (11): 27382747.
NCCN Malignant Peritoneal Mesothelioma 2022 MPEM-C